Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYCNASDAQ:CGCNASDAQ:DNTHNYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$7.85-7.5%$11.23$7.85▼$28.67$543.24M1.12393,711 shs418,321 shsCGCCanopy Growth$1.02+12.1%$1.56$0.88▼$14.92$161.79M0.877.37 million shs7.14 million shsDNTHDianthus Therapeutics$16.83-7.2%$21.78$16.44▼$32.27$540.66M1.82242,358 shs285,845 shsNUVBNuvation Bio$1.76-0.3%$2.16$1.66▼$3.97$594.38M1.471.95 million shs2.92 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics-7.54%-11.30%-28.44%-43.93%-67.63%CGCCanopy Growth+12.09%-7.27%-26.88%-62.77%-86.45%DNTHDianthus Therapeutics-7.22%-7.98%-22.08%-22.80%-43.37%NUVBNuvation Bio-1.13%-9.54%-10.23%-34.02%-52.37%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCYCBicycle Therapeutics1.8773 of 5 stars3.40.00.00.02.42.50.6CGCCanopy Growth2.1457 of 5 stars2.52.00.00.02.20.01.3DNTHDianthus Therapeutics1.36 of 5 stars3.60.00.00.01.81.70.0NUVBNuvation Bio1.8288 of 5 stars3.60.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.75Moderate Buy$29.14271.25% UpsideCGCCanopy Growth 1.00Sell$2.0096.08% UpsideDNTHDianthus Therapeutics 3.22Buy$54.33222.84% UpsideNUVBNuvation Bio 3.25Buy$8.75398.58% UpsideCurrent Analyst Ratings BreakdownLatest CGC, NUVB, DNTH, and BCYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/12/2025DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.00 ➝ $36.003/12/2025DNTHDianthus TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$84.00 ➝ $84.003/12/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/12/2025NUVBNuvation BioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/11/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/11/2025NUVBNuvation BioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/10/2025NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/3/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.002/26/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.002/26/2025BCYCBicycle TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$35.28M15.40N/AN/A$12.35 per share0.64CGCCanopy Growth$276.75M0.58N/AN/A$2.72 per share0.38DNTHDianthus Therapeutics$6.24M86.71N/AN/A$11.40 per share1.48NUVBNuvation Bio$7.87M75.50N/AN/A$2.76 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$180.66M-$2.88N/AN/AN/A-450.64%-27.35%-20.81%5/1/2025 (Estimated)CGCCanopy Growth-$487.23M-$3.80N/AN/AN/A-156.98%-56.52%-24.18%5/29/2025 (Estimated)DNTHDianthus Therapeutics-$43.56M-$2.60N/AN/AN/A-1,250.32%-21.68%-20.88%5/8/2025 (Estimated)NUVBNuvation Bio-$75.80M-$2.26N/AN/AN/AN/A-21.89%-17.86%5/13/2025 (Estimated)Latest CGC, NUVB, DNTH, and BCYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2025Q4 2024DNTHDianthus Therapeutics-$0.85-$0.81+$0.04-$0.81$1.40 million$1.33 million2/25/2025Q4 2024BCYCBicycle Therapeutics-$0.85-$0.75+$0.10-$0.75$5.47 million$3.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A17.1317.13CGCCanopy Growth0.743.522.58DNTHDianthus TherapeuticsN/A18.3018.30NUVBNuvation BioN/A9.579.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%CGCCanopy Growth3.33%DNTHDianthus Therapeutics47.53%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%CGCCanopy Growth1.30%DNTHDianthus Therapeutics16.56%NUVBNuvation Bio5.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.20 million63.18 millionOptionableCGCCanopy Growth3,150158.61 million153.39 millionOptionableDNTHDianthus Therapeutics8032.13 million24.70 millionOptionableNUVBNuvation Bio60338.68 million319.50 millionOptionableCGC, NUVB, DNTH, and BCYC HeadlinesRecent News About These CompaniesNuvation Bio (NYSE:NUVB) Sets New 12-Month Low - Should You Sell?April 1 at 12:45 PM | marketbeat.comNuvation Bio (NYSE:NUVB) Receives "Outperform" Rating from WedbushMarch 28, 2025 | marketbeat.comNuvation Bio Inc. (NYSE:NUVB) Stock Position Boosted by Charles Schwab Investment Management Inc.March 26, 2025 | marketbeat.comInsider Stock Buying Reaches US$720.1k On Nuvation BioMarch 25, 2025 | uk.finance.yahoo.comNuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025March 25, 2025 | businesswire.comStock Traders Buy High Volume of Nuvation Bio Put Options (NYSE:NUVB)March 21, 2025 | marketbeat.comIs Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts?March 17, 2025 | msn.comNuvation Bio (NYSE:NUVB) Shares Down 2.5% - Time to Sell?March 15, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Upgraded to "Strong-Buy" at Jones TradingMarch 15, 2025 | marketbeat.comNuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from AnalystsMarch 13, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Coverage Initiated by Analysts at Jones TradingMarch 13, 2025 | marketbeat.comJones Trading Initiates Coverage of Nuvation Bio (NUVB) with Buy RecommendationMarch 12, 2025 | msn.comQ1 EPS Estimates for Nuvation Bio Lowered by HC WainwrightMarch 12, 2025 | marketbeat.comNuvation Bio initiated with a Buy at JonesResearchMarch 11, 2025 | markets.businessinsider.comNuvation Bio price target lowered to $10 from $11 at H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comNuvation Bio (NYSE:NUVB) Shares Gap Down After Analyst DowngradeMarch 10, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Given New $10.00 Price Target at HC WainwrightMarch 10, 2025 | marketbeat.comQ1 Earnings Estimate for Nuvation Bio Issued By WedbushMarch 10, 2025 | marketbeat.comNuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to AnalystsMarch 9, 2025 | insidermonkey.comNuvation Bio (NYSE:NUVB) Stock Price Up 8% - Still a Buy?March 8, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Releases Earnings Results, Misses Estimates By $0.01 EPSMarch 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGC, NUVB, DNTH, and BCYC Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$7.85 -0.64 (-7.54%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$8.08 +0.23 (+2.93%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Canopy Growth NASDAQ:CGC$1.02 +0.11 (+12.09%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$1.01 -0.01 (-0.98%) As of 06:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Dianthus Therapeutics NASDAQ:DNTH$16.83 -1.31 (-7.22%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$17.40 +0.57 (+3.36%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Nuvation Bio NYSE:NUVB$1.76 -0.01 (-0.28%) Closing price 04/1/2025 03:58 PM EasternExtended Trading$1.74 -0.01 (-0.57%) As of 04/1/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
